CSF1R and neoplasm: This inhibitor has specificity against CSF1R but also the related receptor FLT3 and has been shown to reduce macrophage numbers and limit tumour growth in several models of transplanted tumours as well as in a FLT3-dependent subset of AML (Manthey et al., 2009).